A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits - Wikidata - wikimedia - TriplyDB

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

http://www.wikidata.org/entity/Q35041802

about

Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart.Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia The impact of current and novel anti-diabetic therapies on cardiovascular risk.MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte autophagy.Postconditioning effect of granulocyte colony-stimulating factor is mediated through activation of risk pathway and opening of the mitochondrial KATP channels.Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor.The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.Salidroside attenuates myocardial ischemia-reperfusion injury via PI3K/Akt signaling pathway.

P2860

Q28345454-A2C780F0-32DD-4765-8181-CEC3F1F8B783 Q28367858-872AAEB2-DD37-4F90-9A21-0B6AF7F5EC30 Q32066328-78F82523-CE78-46E5-91D0-E85D55D4D2E9 Q35047390-802282C8-FF4B-4EC5-A436-D3204DF79CAE Q35210037-50792CF9-048A-49E4-AB62-DEC80C2E2473 Q36952365-71D12A8B-E39A-447B-865C-902B54E017DB Q38062033-19CE758B-76B3-415A-8D26-D761511B3A26 Q38830597-BDB55618-6FF8-40F4-8996-38D25DF5D15A Q42943347-AD957C97-49B0-4B17-89B3-31E06E0CA86E Q44654251-CC400C43-627D-4DBE-9E4E-B5EACA916382 Q46712835-2EEB4C6B-13E7-4033-A9AE-469E945E140B Q54448971-5A5561CD-26CC-470B-8F0D-C1F9442907B8

P2860

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

http://www.wikidata.org/entity/Q35041802

description

1999 nî lūn-bûn

@nan

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

@en

type

label

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

@en

prefLabel

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

@en

P1433

Q35041802-93FE9DF2-62FF-4592-A1DF-EF41B6CE56E4

P1476

Q35041802-33FAD82B-7183-42A1-82D2-79B2CEFFDBAE

P2093

Q35041802-0A25DBF3-7846-4B27-BEF9-8D30FDEF6538

Q35041802-0F08EDC5-BB87-4E28-8292-82A9FB8FB196

Q35041802-14601161-E328-46E0-83B1-4E70F2B556E5

Q35041802-31E33C20-73C0-47C8-BB09-EFAB4CD3BE5F

Q35041802-34EB3104-A578-4618-8C1E-48604A1F1743

Q35041802-5BD65515-EC5F-4D1E-8DC8-BE56C3175AC6

Q35041802-7A263799-62C6-4542-8461-BAB186825253

Q35041802-8A06CE65-2146-4AFD-A9E4-0109BA58063B

Q35041802-8FD6F678-E2E9-4222-AAFB-A3643C0D2B01

Q35041802-A60A7E91-2636-4EC2-A72E-AEFE9D8991F1

P2860

Q35041802-09D6EE17-6FE0-46B6-914A-FCF6F891227E

Q35041802-21906A48-5131-4F46-9B69-6A022F84D9A7

Q35041802-263A1472-6083-474B-A4C5-7F9DD21E8595

Q35041802-483794FD-BE80-49A5-8866-72F434063D94

Q35041802-5B3AAF8B-11F4-4758-AA56-235187D1CA48

Q35041802-5FFB84E2-5F0F-424D-BB7A-EEA7570E9DB1

Q35041802-6D327B10-7FC4-45D9-B1B2-8D1F5ECF2734

Q35041802-6F67FC0C-9730-49C5-95EE-72474F9151D0

Q35041802-77F2744D-27E1-47A8-A39A-E8FAE8028F31

Q35041802-7B20F25E-CA6A-4AB5-AF9F-AE55398AE9EC

P304

Q35041802-B481DBAD-3791-45D3-8829-B03A4D4E4C49

P31

Q35041802-BEF5D6E9-43B5-4B9A-9899-DECBDCEF551D

P356

Q35041802-CBD6C4C4-DB7B-462D-98E2-64F489605741

P407

Q35041802-319C133C-B4C7-4E76-828C-E3AF5958FCB5

P433

Q35041802-7B131C44-8615-4849-8BF2-D93B01EC0055

P478

Q35041802-09A1155F-A560-44E9-ABCE-121E884A44E2

P577

Q35041802-AFD73A4F-525E-4966-B9C1-B383B08E1EE3

P5875

Q35041802-3A7E5B88-5A58-45F3-B29E-E9D8E3AA19B5

P698

Q35041802-8D12B116-5CEB-44F7-B0FD-E31F73D48F5F

P932

Q35041802-35122593-3A9A-4E8D-9279-7F847ACF05F8

P356

P1433

British Journal of Pharmacology

P1476

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

@en

P2093

G Takemura

http://www.w3.org/2001/XMLSchema#string

H Fujiwara

http://www.w3.org/2001/XMLSchema#string

K Hashimoto

http://www.w3.org/2001/XMLSchema#string

M Arai

http://www.w3.org/2001/XMLSchema#string

M Kawasaki

http://www.w3.org/2001/XMLSchema#string

S Minatoguchi

http://www.w3.org/2001/XMLSchema#string

T Fujiwara

http://www.w3.org/2001/XMLSchema#string

T Kariya

http://www.w3.org/2001/XMLSchema#string

Y Nishida

http://www.w3.org/2001/XMLSchema#string

Y Uno

http://www.w3.org/2001/XMLSchema#string

P2860

Preconditioning protects ischemic rabbit heart by protein kinase C activation

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.

Pharmacology of alpha-glucosidase inhibition.

New hypoglycaemic agents.

Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning.

Ischemic preconditioning reduces infarct size in swine myocardium.

Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat hearts.

The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme.

P304

1667-1672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0702970

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12712254

http://www.w3.org/2001/XMLSchema#string

P698

10588921

http://www.w3.org/2001/XMLSchema#string

P932

1571807

http://www.w3.org/2001/XMLSchema#string